SNMMI: Study Shows Viability of FAPI PET/CT for Predicting Progressive Pulmonary Fibrosis in Lung Disease Patients
For patients with interstitial lung disease, FAPI PET/CT was more effective than 18F-FDG PET/CT at predicting progressive pulmonary fibrosis according to comparative study findings presented at the 2024 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting.
Emerging research suggests that fibroblast activation protein inhibitor (FAPI) positron emission tomography/computed tomography (PET/CT) may be more advantageous than 18F-FDG PET/CT for early detection of progressive pulmonary fibrosis (PPF) in patients with interstitial lung disease (ILD).
In the comparative study, presented at the 2024 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, researchers reviewed pulmonary function tests and imaging data from 97 patients with ILD who had FAPI PET/CT and 18F-FDG PET/CT.
While both imaging modalities demonstrated an 89 percent specificity rate for predicting PPF, the researchers found that FAPI PET/CT had a significantly higher area under the curve (AUC) than 18F-FDG PET/CT (98 percent vs. 81 percent) and a 33 percent higher sensitivity rate (100 percent vs. 67 percent).
Here one can see 18F-FDG PET/CT and FAPI PET/CT imaging in a 46-year-old man one month after diagnosis of interstitial lung disease (ILD). For this patient, there was an SUVmax (yellow arrow) of 8.3 on FAPI PET/CT in contrast to 4.2 on 18F-FDG PET/CT. (Images courtesy of SNMMI.)
“While 18F-FDG PET/CT can offer some information about ILDs, FAPI PET/CT could provide even more information to physicians, especially regarding progressive pulmonary fibrosis. This could make it a promising diagnostic tool,” noted lead study author Qi Fang, M.D., a resident in the Department of Nuclear Medicine at Guangzhou Medical University in Guangzhou, China.
The researchers noted the whole lung SUVmean (WL-SUVmean) was a key differentiating parameter. Overall, the WL-SUVmean was significantly higher with FAPI PET/CT in comparison to 18F-FDG PET/CT (1.04 vs. 0.82). Patients with PFF demonstrated a higher WL-SUVmean than those without PPF (1.24 vs. 0.73), according to the study authors.
Fang and colleagues suggested the WL-SUVmean could be a “pivotal parameter” with FAPI PET/CT as a key source of metabolic information in patients with ILD.
“These findings underscore the potential utility of FAPI PET/CT as an imaging modality for diagnosing ILD,” said Fang. “In particular, our research shows that patients with high whole-lung SUVmean on FAPI scans tend to manifest progressive pulmonary fibrosis one year later. As such, these patients should be more carefully treated, and anti-fibrosis treatment should begin as early as possible.”
(Editor’s note: For additional content from the SNMMI conference, click here.)
Reference
1. Fang Q, Zhao R, Cui J, et al. Comparative analysis of FDG and FAPI PET/CT imaging in interstitial lung disease: focused on progressive pulmonary fibrosis prediction. Presented at the 2024 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, June 8-11, Toronto, Canada. Available at: https://www.xcdsystem.com/snmmi/program/10OD8Tq/index.cfm?pgid=1579&RunRemoveSessionFilter=1 . Accessed June 8, 2024.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
SNMMI: Can Multimodal Monitoring Bolster Outcomes with Pluvicto in Treating mCRPC?
June 22nd 2025Multimodal treatment monitoring, including SPECT/CT exams 24 hours after treatment with Lu-177 PSMA-617, may have facilitated significantly shorter therapy durations and reduced side effects in patients with mCRPC, according to a two-year study presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
